meldonium
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
3
Earliest trial started Apr 1, 2016 (NCT02758912)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Gamma-butyrobetaine dioxygenaseINHIBITOR
BBOX1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- trimethylhydrazinium propionate dihydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05939622 | Phase 4 | May 18, 2022 | Promomed, LLC |
| NCT05689827 | Phase 4 | Apr 5, 2022 | Promomed, LLC |
| NCT02758912 | Phase 4 | Apr 1, 2016 | Burnasyan Federal Medical Biophysical Center |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Promomed, LLC | For profit | 2 | 2 | 1 | 2022 |
| Burnasyan Federal Medical Biophysical Center | Government | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1